Melanoma: What do all the mutations mean?

Elizabeth J. Davis, Douglas B. Johnson*, Jeffrey A. Sosman, Sunandana Chandra

*Corresponding author for this work

Research output: Contribution to journalReview article

20 Scopus citations


Melanoma is one of the most highly mutated malignancies, largely as a function of its generation through ultraviolet light and other mutational processes. The wide array of mutations in both “driver” and “passenger” genes can present a confusing array of data for practitioners, particularly within the context of the recent revolutions in targeted and immune therapy. Although mutations in BRAF V600 clearly confer sensitivity to BRAF and mitogen-activated protein kinase kinase (MEK) inhibitors, the clinical implications of most other mutations are less often discussed and understood. In this review, we provide an overview of the high-frequency genomic alterations and their prognostic and therapeutic relevance in melanoma.

Original languageEnglish (US)
Pages (from-to)3490-3499
Number of pages10
Issue number17
StatePublished - Sep 1 2018


  • BRAF
  • KIT
  • NRAS
  • cyclin-dependent kinase inhibitor 2A (CDKN2A)
  • melanoma
  • mutation
  • programmed cell death protein 1 (PD-1)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Melanoma: What do all the mutations mean?'. Together they form a unique fingerprint.

  • Cite this